Shilpa CDMO's $50 million plan adds 10 kL of SPPS reactor capacity in Raichur, India, with its first commercial peptide line opening in December 2026.
|Articles|February 15, 2002
- BioPharm International-02-01-2002
- Volume 15
- Issue 2
The Immunogenicity of Therapeutic Proteins
Author(s)Fiona Adair, Daniel Ozanne
By Fiona Adair and Daniel Ozanne,Biovation Ltd., pp. 30-36. Immunogenicity is often a barrier to further development of potentially therapeutic proteins. That barrier often remains unknown until late in the development chain. The authors explore various strategies for preventing immunogenicity and for predicting it earlier in the process.
Advertisement
Articles in this issue
over 24 years ago
Outsourcing Outlook: Reaping the Benefits of E-Procurementover 24 years ago
Inside Washington: Costs and Controls Challenge Manufacturersover 24 years ago
21 CFR Part 11: (Un)Expected Added ValueAdvertisement
Related to this article
Today’s BioPharm Brief covers FDA’s final potency assurance guidance for cell and gene therapies, Lonza’s deal to acquire Merck KGaA’s US CDMO business, and Phase 2a data for Tiziana’s intranasal anti-CD3 antibody foralumab in progressive multiple sclerosis.
At AAPS PharmSci 360 2026, University of Iowa PhD candidate Siddhanth Hejmady explains how adding a payload or radiolabel to trastuzumab changes its behavior in bulk solution and at interfaces, and why developability teams should pair DLS with QCM-D.
Final FDA guidance replaces 2011 potency testing advice, asking CGT makers to build potency assurance from IND filing through postmarket monitoring.
Teva will commercialize etanercept-ykro (Eticovo) and infliximab-abda, adding 2 TNF inhibitor biosimilars to US options for inflammatory diseases.
In the Phase 2a INFORM-MS trial, Tiziana’s nasal foralumab reduced microglial activation on PET imaging at 50 µg in non-active secondary progressive MS, while the 100-µg dose showed no significant effect.
The deal adds five US sites and about 1,100 employees, more than doubling Lonza’s US network and filling a gap in US bioconjugation capacity the company flagged weeks earlier.
CAR-T transformed blood cancer care, but solid and brain tumors demand different delivery, manufacturing, and safety strategies to work.
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Finalizes Potency Assurance Guidance for Cell and Gene Therapies
2
Fresenius and WuXi Biologics Sign Exclusive Agreement Covering Up to 37 Biosimilar Candidates
3
Lonza to Acquire Merck KGaA’s US CDMO Business, Adding ADC, Viral Vector, and LNP Capacity
4
FDA Accepts uniQure’s Huntington’s Disease Gene Therapy BLA for Priority Review
5